C4 Therapeutics (CCCC) Income towards Parent Company (2019 - 2026)

C4 Therapeutics' Income towards Parent Company history runs 8 years deep, the most recent figure standing at -$27.4 million for Q1 2026.

• In Q1 2026, Income towards Parent Company fell 4.27% year-over-year to -$27.4 million; the TTM figure through Mar 2026 stood at -$106.0 million (down 2.63% YoY), while the FY2025 annual figure was -$105.0 million, changed 0.31% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$27.4 million, down from -$20.4 million in the prior quarter.
• The five-year high for Income towards Parent Company was -$17.7 million in Q2 2024, with the low at -$128.7 million in Q2 2022.
• The 5-year median for Income towards Parent Company is -$31.6 million (2022), against an average of -$35.3 million.
• The sharpest annual moves came in 2022 and 2023: Income towards Parent Company tumbled 469.84% in 2022, then jumped 72.08% in 2023.
• C4 Therapeutics' Income towards Parent Company stood at -$37.2 million in 2022, then grew by 6.53% to -$34.8 million in 2023, then grew by 0.53% to -$34.6 million in 2024, then surged by 41.1% to -$20.4 million in 2025, then tumbled by 34.77% to -$27.4 million in 2026.
• Business Quant data shows CCCC's Income towards Parent Company at -$27.4 million in Q1 2026, -$20.4 million in Q4 2025, and -$32.2 million in Q3 2025.